Ustekinumab
Brand: Stelara
Class: Immunomodulator
Subclass: IL-12/IL-23 monoclonal antibody
PK:
t½ 21 days | Clearance: reticuloendothelial
Max Dose: not added
moderate
AE: Infections (URTI), injection-site reactions, malignancy risk (rare), reversible posterior leukoencephalopathy syndrome (very rare)